Temasek unit invests $5m in HC Surgical Specialists

It will be done through a 3-year 5.5% convertible bond at a conversion price of $0.54 per share.

Heliconia, a subsidiary of Temasek providing growth capital for Singapore’s small and medium-sized enterprises, has invested $5m in medical services group HC Surgical Specialists (HCSS).

The investment will be done through a three-year 5.5% convertible bond at a conversion price of $0.54 per share. Heliconia will also receive a three-year option to subscribe for up to $5m of new ordinary shares in HCSS for an exercise price of $0.62/share.

Founded in 2016, HCSS currently has 16 clinics in Singapore and serves as the exclusive provider of colorectal cancer screening for eligible clients of the life insurance firm AIA Singapore.

HCSS CEO Heah Sieu Min said that the company will use funds for services to clients in Singapore and overseas markets.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia